profit from every $100 of sales.
$0$100
Bolt Biotherapeutics
$5.91-5.59% today
+26.0% in 1 year
1-year low $3.181-year high $7.09
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Bolt Biotherapeutics sold, what it kept, and what it did with the cash.
Sales went from $5.73 million in 2022 to $7.70 million in 2025, with -$33.4 million of profit last year.
SalesProfit
Bolt Biotherapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Bolt Biotherapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 34.8× · Expensive | ||
 Regeneron Pharmaceuticals | 21.8× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.3× · Fair price |
AI analysis
An AI analyst reads Bolt Biotherapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 6 | 8 | 8 | 8 | |
| – | – | – | – | |
| -90 | -76 | -68 | -35 | |
| -89 | -74 | -66 | -33 | |
| -88 | -69 | -63 | -33 | |
| -47.20 | -36.60 | -33.00 | -17.85 | |
| – | – | – | – | |
| -1,576.6% | -967.4% | -887.3% | -450.1% | |
| -1,537.8% | -878.6% | -820.8% | -433.7% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 228 | 160 | 100 | 57 |
| Cash | 9 | 11 | 7 | 12 |
| Total debt | 23 | 20 | 25 | 23 |
| Total liabilities | 56 | 47 | 42 | 30 |
| 172 | 113 | 57 | 27 | |
| 2 | 2 | 2 | 2 | |
| -36.8% | -45.3% | -65.4% | -55.3% | |
| -51.4% | -61.4% | -110.4% | -125.9% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -77 | -70 | -61 | -40 | |
| 2 | 0 | 0 | 0 | |
| -78 | -70 | -61 | -40 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 10 | 9 | 7 | 3 |
Valuation
- –
- –
- –
- 4.0×
- 1.8×
- –
- –
- -286.6%
- -239.6%
- 0.0%
Profitability
- 76.7%
- -450.1%
- -433.7%
- -441.1%
- -69.0%
- -55.5%
- -100.9%
- -61.6%
- -74.0%
- 362.5%
Growth
- +10.3%
- –
- +34.9%
- –
- −52.7%
Financial health
- –
- 1.13
- 46.4%
- –
- 3.51
- 3.51
- 0.14
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 3%of 952
Bottom 46%of 870
What analysts expect
- Average price target
- $4.00
- Range
- $1.00 – $7.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 12, 2026 | -4.31 | -2.85 | −51.2% |
| Mar 12, 2026 | -3.84 | -4.30 | +10.7% |
| Nov 12, 2025 | -3.72 | -5.07 | +26.6% |
| Aug 14, 2025 | -4.46 | -6.40 | +30.3% |
| May 12, 2025 | -5.80 | -6.80 | +14.7% |
| Mar 24, 2025 | -7.60 | -7.60 | +0.0% |
| Nov 12, 2024 | -0.40 | -0.36 | −11.1% |
| Aug 13, 2024 | -0.56 | -0.54 | −3.7% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
47No pass
Benjamin Graham
35No pass
Philip Fisher
50No pass
Peter Lynch
36No pass
Joel Greenblatt
0No pass
Charlie Munger
40No pass
Terry Smith
50No pass
Questions about Bolt Biotherapeutics
Is Bolt Biotherapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Bolt Biotherapeutics AI analysis
What does Bolt Biotherapeutics do?
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. It is in Biotechnology.
Does Bolt Biotherapeutics pay a dividend?
No. Bolt Biotherapeutics does not pay a dividend at the moment.
Is Bolt Biotherapeutics stock halal?
No. Bolt Biotherapeutics does not pass our halal screen: its debt is 165% of its market value, at or above the 33% limit. How we check
How has Bolt Biotherapeutics stock done over the past year?
Up 26.0% over the past twelve months, to $5.91. It traded between $3.18 and $7.09 and is 16.6% below its high.
Who are Bolt Biotherapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Bolt Biotherapeutics's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.